Long-term incidence and predictive factors of thromboembolic events after a cryoballoon ablation for atrial fibrillation.


Journal

International journal of cardiology
ISSN: 1874-1754
Titre abrégé: Int J Cardiol
Pays: Netherlands
ID NLM: 8200291

Informations de publication

Date de publication:
15 Dec 2020
Historique:
received: 23 04 2020
revised: 18 06 2020
accepted: 07 08 2020
pubmed: 19 8 2020
medline: 15 5 2021
entrez: 19 8 2020
Statut: ppublish

Résumé

Long-term outcomes in terms of thromboembolic events (TEs) are poorly described after cryoballoon pulmonary vein isolation (cryo-PVI) for atrial fibrillation (AF). We evaluated the long-term incidence and predictive factors of TE after cryo-PVI. All consecutive patients who underwent cryo-PVI for paroxysmal or persistent AF between November 2012 and October 2017 were included. They were prospectively followed for at least 12 months in the ablation center and then by their cardiologist. Data on all ischemic events (stroke, transient ischemic attack (TIA), systemic embolism) were collected. In total, 450 patients (78% men, median age 61 years) were included. The mean CHA The long-term incidence of TEs after cryo-PVI was 0.53%/year. The CHA

Sections du résumé

BACKGROUND BACKGROUND
Long-term outcomes in terms of thromboembolic events (TEs) are poorly described after cryoballoon pulmonary vein isolation (cryo-PVI) for atrial fibrillation (AF). We evaluated the long-term incidence and predictive factors of TE after cryo-PVI.
METHODS METHODS
All consecutive patients who underwent cryo-PVI for paroxysmal or persistent AF between November 2012 and October 2017 were included. They were prospectively followed for at least 12 months in the ablation center and then by their cardiologist. Data on all ischemic events (stroke, transient ischemic attack (TIA), systemic embolism) were collected.
RESULTS RESULTS
In total, 450 patients (78% men, median age 61 years) were included. The mean CHA
CONCLUSION CONCLUSIONS
The long-term incidence of TEs after cryo-PVI was 0.53%/year. The CHA

Identifiants

pubmed: 32810541
pii: S0167-5273(20)33532-4
doi: 10.1016/j.ijcard.2020.08.005
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

99-103

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Auteurs

Alexis Hermida (A)

Cardiac Arrhythmia Service, Amiens-Picardie University Hospital, France. Electronic address: a.hermida.jarry@gmail.com.

Mustafa Zaitouni (M)

Cardiac Arrhythmia Service, Amiens-Picardie University Hospital, France.

Momar Diouf (M)

Cardiac Arrhythmia Service, Amiens-Picardie University Hospital, France.

Pierre-Marc Lallemand (PM)

Cardiac Arrhythmia Service, Amiens-Picardie University Hospital, France.

Floriane Fay (F)

Cardiac Arrhythmia Service, Amiens-Picardie University Hospital, France.

Otilia Buiciuc (O)

Cardiac Arrhythmia Service, Amiens-Picardie University Hospital, France.

Maciej Kubala (M)

Cardiac Arrhythmia Service, Amiens-Picardie University Hospital, France.

Jean-Sylvain Hermida (JS)

Cardiac Arrhythmia Service, Amiens-Picardie University Hospital, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH